Trailblazer Acquisition Corp. filed a Form 10-Q with the SEC on November 13, 2026, covering the quarterly period ended September 30, 2026, for the blank-check company incorporated in the Cayman Islands and listed on NASDAQ:BLZR.
Royalty Management Holding Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting condensed consolidated financial results and balance sheet data for the third quarter.
Seneca Bancorp, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting consolidated results for the three and nine months ended on that date.
Snow Rothschild Acquisition Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, covering its first months of operations following an initial public offering completed in June 2026.
BM Acquisition Corp. filed a Form 10-Q with the SEC on November 13, 2026, covering the quarterly period ended September 30, 2026, disclosing its financial position as a blank check company incorporated in the Cayman Islands that had not yet commenced operations.
Accelevation Holdings Corp. filed its quarterly report for the period ended September 30, 2026, with the SEC on November 13, 2026, covering the company's first reporting period since its formation as a Delaware corporation on June 15, 2026.
Boston Omaha Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting a net loss attributable to common stockholders of $192 thousand for the third quarter.
EGH Acquisition Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, covering operations as a Cayman Islands exempted company listed on Nasdaq.
OptimizeRx Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting net income of $1.195 million for the third quarter and essentially breakeven results for the nine months year-to-date.
TherapeuticsMD, Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026.